Endo International plc commented on the United States District Court for the District of Delaware’s non-infringement ruling in favor of Eagle Pharmaceuticals Inc. (“Eagle”) in patent litigation regarding Eagle’s abbreviated new drug application, or ANDA, for Par Sterile Products, LLC’s VASOSTRICT® product. Because the court found non-infringement of Endo’s patents by Eagle’s proposed product, it did not rule on the patents’ validity.
“We are disappointed in today’s ruling and respectfully disagree with the court’s decision,” said Matthew J. Maletta, Executive Vice President and Chief Legal Officer of Endo. “We note that the decision turned on the court’s interpretation of conflicting appellate case law. Specifically, the court stated that after expending significant effort, it remained unable to reconcile appellate case law governing the consideration of product testing data which differs from ANDA specifications. We plan to address that important issue, among others, as we appeal today’s decision and continue defending our intellectual property rights to VASOSTRICT®.”
About Endo International plc
Endo International plc is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com